DexCom earnings beat by $0.03, revenue topped estimates
In recent transactions, Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), sold 4,000 shares of the company’s common stock. The sales occurred over two consecutive days, March 5 and March 6, 2025, and were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024. The transactions come as the stock has declined nearly 8% over the past week, according to InvestingPro data.
On March 5, Songjiang sold 2,000 shares at a weighted average price of $10.98 per share, with prices ranging from $10.63 to $11.23. The following day, another 2,000 shares were sold at an average price of $10.80 per share, with prices between $10.63 and $11.17. The total value of these transactions amounted to $43,560. The stock currently trades at $10.32, below the insider’s sale prices, with InvestingPro analysis suggesting the stock is slightly overvalued.
After these sales, Songjiang’s indirect ownership, through his spouse, stands at 2,843,260 shares. These transactions are part of a pre-established trading plan, providing a structured approach to managing stock sales. The company, currently valued at $874 million, maintains a FAIR financial health score according to InvestingPro’s comprehensive analysis framework.
In other recent news, Gyre Therapeutics announced the appointment of Ping Zhang as the lead independent director of its Board of Directors. Zhang, who has a strong financial background, will also serve on the Nominating and Corporate Governance Committee. In addition to this leadership change, Ying Luo has stepped down as Chairman of Gyre Pharmaceuticals, a subsidiary of Gyre Therapeutics, to focus on his role at GNI Group Ltd. Songjiang Ma has been appointed as the new Chairman for Gyre Pharmaceuticals. Gyre Pharmaceuticals is actively advancing its pipeline in China, including ongoing clinical trials for F351 and the commercialization of ETUARY® (Pirfenidone capsule), with 2023 net sales reaching $112.1 million. The company is also developing treatments for conditions such as COPD, PAH, and ALF/ACLF. These developments are part of Gyre Therapeutics’ broader strategy informed by its mechanistic and clinical studies related to liver fibrosis. The information for this report is based on a press release statement from Gyre Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.